Taro Pharmaceutical Industries Ltd
Change company Symbol lookup
Select an option...
TARO Taro Pharmaceutical Industries Ltd
ISCRF iShares Global Corp Bond UCITS ETF USD Dist
VLNSF Velan Inc
VIRX Viracta Therapeutics Inc
ERJ Embraer SA
BNMV BitNile Metaverse Inc
FCF First Commonwealth Financial Corp
ARMN Aris Mining Corp

Health Care : Pharmaceuticals | Small Cap Value
Based in Israel
Company profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.


Last Trade
-0.14 (-0.38%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.14 (-0.38%)
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
July 26, 2023
Taro Provides Results for the Quarter Ended June 30, 2023

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter ended June 30, 2023. Quarter ended June 30, 2023 Highlights - compared to June 30, 2022 (BusinessWire)

July 19, 2023
Taro to Release First Quarter Results on July 26, 2023

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023. (BusinessWire)

Krensavage Asset Management Opposes Sun's Lowball Bid for Taro

As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun Pharmaceutical Industries Ltd.'spaltry bid to take Taro private. Sun, a 78.5% Taro shareholder, on May 26 offered...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.